Accolade

Accolade, Inc. engages in the provision of personalized health and benefits solutions. Its products include Accolade Total Benefits, which is designed for employers with low employee adoption of healthcare and benefits programs, Accolade Total Care, which focuses on influencing the actual interactions between employees and providers, and are also interested in care management services, and Accolade Total Health and Benefits, which offers a full suite of solutions. The company was founded by Thomas K. Spann, J. Michael Cline, and Sudhir Steven Singh in 2007 and is headquartered in Seattle, WA.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Accolade reports strong Q4 performance, faces market challenges ahead

Accolade's transformation into a personalized healthcare company has shown strong growth and improved financial performance. The company faces challenges related to operational excellence, market strategy, and the impact of industry decisions. However, opportunities lie in leveraging technology for healthcare and the upcoming Capital Markets Day to showcase growth prospects.

Accolade exceeds Q3 revenue guidance, eyes profitability by fiscal '25

Accolade's Q3 earnings call highlighted strong performance, diverse customer relationships, and growth opportunities in government business and virtual care. The company aims to achieve profitability by fiscal '25 through strategic investments and operational improvements, leveraging its competitive advantage in delivering ROI and performance guarantees.

Accolade reports robust Q4 performance, eyes tech-driven growth opportunities

Accolade's Q4 2023 Earnings Call highlighted strong financial performance, customer focus, and strategic initiatives. The company faces challenges in timing performance guarantees but sees opportunities in technology adoption and growth strategies.

Accolade surpasses Q1 expectations, eyes growth in healthcare partnerships

Accolade's Q1 performance exceeded expectations, with a focus on growth drivers and streamlining decision-making. Despite challenges in the government business, the company is optimistic about future growth opportunities and customer acquisition. Improved guidance and a strong pipeline indicate a positive outlook for the year.

Accolade beats Q2 revenue targets, eyes profitability in fiscal '25

Accolade exceeded revenue and EBITDA expectations in Q2, driven by strong customer additions and unique service offerings. Despite challenges from drug impacts and contract disputes, the company maintains its full-year guidance and eyes profitability in fiscal '25.

Accolade excels in Q3, eyes automation for growth opportunities

Accolade's Q3 performance exceeded expectations, with a positive outlook for future revenue and EBITDA. Differentiation in services and technology integration drive operational excellence. Uncertainty around TRICARE contract and focus on automation and growth opportunities.

Accolade reports robust Q4 earnings, eyes sustainable growth in '25

Accolade's strong performance in Q4 2024 sets a positive trajectory for fiscal year '25, with a focus on sustainable growth and profitability. The company's strategic strengths in serving a large customer base, successful partnerships, and innovative offerings position it well for future opportunities despite challenges in meeting revenue guidance and addressing post-security breach concerns.

Accolade reports strong Q2 earnings, focuses on profitability and growth

Accolade's Q2 performance exceeded expectations, emphasizing profitability and member experience.
The company's strengths lie in revenue growth, cost management, and competitive wins.
Challenges include cost structure management and balancing growth with profitability.
Opportunities exist in enhancing member experience, expanding partnerships, and driving sustainable growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Accolade, Inc. engages in the provision of technology-enabled health and benefits solutions. The company was founded by Thomas K. Spann and J. Michael Cline in January 2007 and is headquartered in Seattle, WA.

SEATTLE, April 23, 2021 (GLOBE NEWSWIRE) -- Accolade, Inc. (Nasdaq: ACCD), the company reinventing healthcare by helping people live their healthiest lives, today announced it has signed a definitive agreement to acquire PlushCare, a leading provider of virtual primary care and mental health treatment. Together, the two companies intend to provide more seamless consumer access to care for acute, chronic, and preventive health needs with highly rated physicians whether delivered through a virtual setting with PlushCare, or through Accolade's advocacy and navigation solutions that support in-person consultation. The addition of a primary care team will extend Accolade's ability to improve clinical health outcomes for its members and deliver additional cost savings for employers.

Accolade to Acquire PlushCare

Accolade has seen solid growth throughout the second half of 2020, now accompanied by some margin improvements as well.

Accolade: Interesting And Solid Healthcare Play

SEATTLE, March 25, 2021 (GLOBE NEWSWIRE) -- Accolade, Inc. (Nasdaq: ACCD) (“Accolade”) announced the pricing of $250 million aggregate principal amount of 0.50% convertible senior notes due 2026 (the “Notes”) in a private placement (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Accolade also granted the initial purchasers of the Notes an option to purchase, within a 13-day period beginning on, and including, the date on which the Notes are first issued, up to an additional $37.5 million aggregate principal amount of the Notes. The sale of the Notes is expected to close on March 29, 2021, subject to customary closing conditions.

Accolade Announces Pricing of $250 Million Convertible Senior Notes Offering

SEATTLE, March 23, 2021 (GLOBE NEWSWIRE) -- Accolade, Inc. (Nasdaq: ACCD) today provided preliminary unaudited financial results for the fiscal fourth quarter and year ended February 28, 2021 (fiscal year 2021). Based on current information, the company expects to report revenue for the fiscal 2021 fourth quarter in the range of $56.9 million to $57.9 million and revenue for fiscal year 2021 in the range of approximately $168.0 million to $169.0 million. The company expects to report net loss for the fiscal 2021 fourth quarter in the range of $(7.1) million to $(5.6) million and net loss for fiscal year 2021 in the range of $(53.0) million to $(51.5) million. Adjusted EBITDA is expected to be in the range of $0.6 million to $2.1 million for the fiscal 2021 fourth quarter and in the range of $(29.0) million to $(27.5) million for fiscal year 2021.

Accolade Announces Preliminary Results for Fourth Quarter and Full Year of Fiscal Year 2021

SEATTLE, March 23, 2021 (GLOBE NEWSWIRE) -- Accolade, Inc. (Nasdaq: ACCD) (“Accolade”) announced today that it intends to offer, subject to market and other conditions, $250 million aggregate principal amount of convertible senior notes due 2026 (the “Notes”) in a private placement (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Accolade also intends to grant the initial purchasers of the Notes an option to purchase, within a 13-day period beginning on, and including, the date on which the Notes are first issued, up to an additional $37.5 million aggregate principal amount of the Notes.

Accolade Announces Private Offering of $250 Million Convertible Notes

Healthcare technology company Accolade is buying telemedicine startup 2nd.MD to boost its abilities to help users navigate medical plans and second options, CNBC reported. The sale is likely to go forward for $460 million, according to CNBC, and Accolade will purchase 2nd.MD parent company Innovation Specialists.

Accolade To Buy 2nd.MD To Boost Telehealth Options

Seattle-based Accolade announced Thursday that it will pay $460 million acquire 2nd.

Health benefits platform Accolade will pay $460M to acquire telemedicine startup 2nd.MD

Accolade Inc. said late Thursday it has agreed to buy Innovation Specialists LLC, which does business as 2nd.MD, a "leading" expert medical opinion and medical decision support company based in Houston, for $460 million. The deal is expected to close by the end of February, and under the terms of the agreement, Accolade will pay $230 million in cash, $130 million in Accolade stock, and up to $100 million of Accolade stock payable upon certain revenue milestones after the closing.

Accolade agrees to buy medical-expert company for $460 million

The addition of 2nd.MD's Expert Medical Opinion services to Accolade's portfolio of high-touch, technology-enabled health and benefits solutions expands Accolade's clinical capabilities and creates the market's most comprehensive, integrated healthcare navigation experience.

Accolade to Acquire 2nd.MD

Just as the digitization of finance has attracted billions in investment and a flurry of M&A, health tech has seen a surge in interest during the pandemic.

Healthtech firm Accolade is buying telemedicine start-up 2nd.MD for $460 million, sources say

Accolade integrates workplace benefits into one platform and helps organizations save on employee healthcare costs through a virtual concierge service. The company launched its IPO in July of 2020 and is presenting strong growth with a positive operational outlook.

Accolade Inc.: Bullish Outlook As Its HealthTech Platform Helps Companies Save

SEATTLE, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), which provides personalized, technology-enabled solutions that help people better understand, navigate, and utilize the healthcare system and their workplace benefits, will participate in the 39th Annual J.P. Morgan Healthcare Conference, including a presentation on Thursday, January 14, 2021 at 2:50 p.m. E.T. An audio webcast and related presentation materials will be available at ir.accolade.com.

Accolade to Participate in 39th Annual J.P. Morgan Healthcare Conference

Accolade, Inc. (ACCD) CEO Rajeev Singh on Q3 2021 Results - Earnings Call Transcript

SEATTLE, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), which provides personalized, technology-enabled solutions that help people better understand, navigate, and utilize the healthcare system and their workplace benefits, today announced financial results for the fiscal third quarter ended November 30, 2020.

Accolade Announces Results for Fiscal Third Quarter 2021

SEATTLE, Dec. 23, 2020 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), which provides personalized, technology-enabled solutions that help people better understand, navigate, and utilize the healthcare system and their workplace benefits, today announced that it will release fiscal third quarter 2021 financial results on Thursday, January 7, 2021, after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. E.T. on the same day.

Accolade to Announce Fiscal Third Quarter 2021 Financial Results

SEATTLE, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), which provides personalized, technology-enabled solutions that help people better understand, navigate, and utilize the healthcare system and their workplace benefits, will participate in the William Blair Healthcare 2021 Focus List Event, including a fireside chat presentation by Rajeev Singh, Chief Executive Officer, on Thursday, December 17, 2020. An audio replay will be made available at ir.accolade.com shortly after the event.

Accolade to Participate in William Blair Healthcare 2021 Focus List Event

SEATTLE, Nov. 20, 2020 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), which provides personalized, technology-enabled solutions that help people better understand, navigate, and utilize the healthcare system and their workplace benefits, will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference, including a fireside chat presentation, on Tuesday, December 1, 2020. An audio replay and related presentation materials will be available at ir.accolade.com.

Accolade to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference

SEATTLE, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), which provides personalized, technology-enabled solutions that help people better understand, navigate, and utilize the healthcare system and their workplace benefits, will participate in the virtual 29th Annual Credit Suisse Healthcare Conference, including a fireside chat presentation on Wednesday, November 11, 2020 at 10:15 a.m. E.T. An audio webcast and related presentation materials will be available at ir.accolade.com.

Accolade to Participate in the 29th Annual Credit Suisse Healthcare Conference

SEATTLE, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Accolade, Inc. (Nasdaq: ACCD), which provides personalized, technology-enabled solutions that help people better understand, navigate, and utilize the healthcare system and their workplace benefits, today announced the closing of its public offering of 5,750,000 shares of its common stock, inclusive of the full exercise by the underwriters of their option to purchase 750,000 shares of common stock, at a price to the public of $38.50 per share. The aggregate gross proceeds to Accolade from the offering, before deducting the underwriting discount and other offering expenses, were approximately $221.4 million.

Accolade Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

SEATTLE, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Accolade, Inc. (“Accolade”), which provides personalized, technology-enabled solutions that help people better understand, navigate, and utilize the healthcare system and their workplace benefits, today announced the pricing of its previously announced underwritten public offering of 5,000,000 shares of its common stock at a price to the public of $38.50 per share. The offering is expected to close on October 26, 2020, subject to customary closing conditions. In addition, Accolade has granted the underwriters a 30-day option to purchase up to 750,000 additional shares of its common stock at the public offering price, less the underwriting discount.

Accolade Announces Pricing of Public Offering of Common Stock

SEATTLE, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Accolade, Inc. (“Accolade”), which provides personalized, technology-enabled solutions that help people better understand, navigate, and utilize the healthcare system and their workplace benefits, today announced it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission for a proposed public offering of 4,500,000 shares of its common stock. In addition, Accolade expects to grant the underwriters a 30-day option to purchase up to 675,000 additional shares of its common stock at the public offering price, less the underwriting discount. The public offering price has not yet been determined. The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Accolade Announces Proposed Public Offering of Common Stock

Accolade, Inc. (ACCD) CEO Rajeev Singh on Q2 2021 Results - Earnings Call Transcript

Health benefits technology company Accolade saw revenue rise 24% in the most recent quarter as telehealth usage surges amid the COVID-19 pandemic.

Health benefits tech company Accolade sees revenue rise 24% to $36.8M in Q3, but stock dips

SEATTLE, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), which provides personalized, technology-enabled solutions that help people better understand, navigate, and utilize the healthcare system and their workplace benefits, today announced financial results for the fiscal second quarter ended August 31, 2020.

Accolade Announces Results for Fiscal Second Quarter 2021

SEATTLE, Sept.  24, 2020  (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), which provides personalized, technology-enabled solutions that help people better understand, navigate, and utilize the healthcare system and their workplace benefits, today announced that it will release fiscal second quarter 2021 financial results on Wednesday, October 14, 2020, after the market closes. In conjunction, the company will host a conference call to review results at 5:00 p.m. E.D.T. on the same day.

News for Accolade Stock (ACCD)